Related references
Note: Only part of the references are listed.OPTN/SRTR 2011 Annual Data Report: Kidney
A. J. Matas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates
Vinay Nair et al.
CLINICAL TRANSPLANTATION (2012)
Infusion of High-Dose Intravenous Immunoglobulin Fails to Lower the Strength of Human Leukocyte Antigen Antibodies in Highly Sensitized Patients
Nada Alachkar et al.
TRANSPLANTATION (2012)
Lack of Effect in Desensitization With Intravenous Immunoglobulin and Rituximab in Highly Sensitized Patients
Kwaku Marfo et al.
TRANSPLANTATION (2012)
Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis
Alejandro M. Gomez et al.
JOURNAL OF IMMUNOLOGY (2011)
Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition
R. Carlin Walsh et al.
TRANSPLANTATION (2011)
Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection
R. Carlin Walsh et al.
TRANSPLANTATION (2010)
Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
Ashley A. Vo et al.
TRANSPLANTATION (2010)
Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production
D. K. Perry et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Living Donor Kidney Transplantation Across Positive Crossmatch: The University of Illinois at Chicago Experience
James J. Thielke et al.
TRANSPLANTATION (2009)
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development
D. Maseda et al.
CELL DEATH AND DIFFERENTIATION (2008)
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Matthew J. Everly et al.
TRANSPLANTATION (2008)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effect of desensitization protocols on human splenic B-cell populations in vivo
E. J. Ramos et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin
AA Zachary et al.
HUMAN IMMUNOLOGY (2005)
Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study
L Almadrones et al.
ONCOLOGY NURSING FORUM (2004)
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics
CA Vieira et al.
TRANSPLANTATION (2004)
Evaluation of intravenous immunoglobulin as are agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIHIG02 trial
SC Jordan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Overcoming a positive crossmatch in living-donor kidney transplantation
JM Gloor et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients
RA Montgomery et al.
TRANSPLANTATION (2000)
Share Paper
